Title:
COMBINATION OF AN ACAT1 INHIBITOR AND A CYP1 1 B1 INHIBITOR FOR TREATING DISORDERS ASSOCIATED WITH EXCESS CORTISOL PRODUCTION
Document Type and Number:
WIPO Patent Application WO/2016/164476
Kind Code:
A3
Abstract:
A therapeutically effective amount of a combination of: (a) an inhibitor of CYP11B1; and (b) ACAT1 inhibitor N-(2,6-bis(l-methylethyl) phenyl)-N'-((l-(4-(dimethylamino)phenyl)cyclopentyl)-methyl) urea (ATR-101) or a salt thereof; or (a) an inhibitor of CYP11B1; (b) an inhibitor of CYP11B2; and (c) ACAT1 inhibitor N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4-(dimethyl-lamino)phenyl)cyclopentyl) -methyl)urea or a salt thereof for use in a method for the treatment of disorders associated with excess Cortisol production, including treatment of Cushing's syndrome.
Inventors:
MOHIDEEN PHARIS (US)
OWENS JULIA CHRISTINE (US)
OWENS JULIA CHRISTINE (US)
Application Number:
PCT/US2016/026240
Publication Date:
December 01, 2016
Filing Date:
April 06, 2016
Export Citation:
Assignee:
MILLENDO THERAPEUTICS INC (US)
International Classes:
A61K31/17; A61K31/4184; A61K31/444; A61K45/06; A61P5/06; A61P5/26; A61P5/42; A61P5/46
Domestic Patent References:
| WO2013142214A1 | 2013-09-26 | |||
| WO2016049518A1 | 2016-03-31 |
Other References:
L. GHATAORE ET AL: "Effects of mitotane treatment on human steroid metabolism: implications for patient management", ENDOCRINE CONNECTIONS, vol. 1, no. 1, 1 July 2012 (2012-07-01), pages 37 - 47, XP055307263, DOI: 10.1530/EC-12-0028
XAVIER BERTAGNA ET AL: "LCI699, a Potent 11[beta]-hydroxylase Inhibitor, Normalizes Urinary Cortisol in Patients With Cushing's Disease: Results From a Multicenter, Proof-of-Concept Study", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 99, no. 4, 1 April 2014 (2014-04-01), US, pages 1375 - 1383, XP055307207, ISSN: 0021-972X, DOI: 10.1210/jc.2013-2117
COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS: "Public summary of opinion on orphan designation Osilodrostat for the treatment of Cushing's syndrome", 10 November 2014 (2014-11-10), pages 1 - 4, XP055307204, Retrieved from the Internet [retrieved on 20161003]
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; BAILIE, MARC B. (CORRESPONDENCE) ET AL: "ATR - 101 , a selective ACAT1 inhibitor in development for adrenocortical carcinoma, disrupts steroidogenesis and causes apoptosis in normal canine adrenals.", XP002762495, retrieved from STN Database accession no. 0052299841
L.A. VERNETTI ET AL: "Differential toxicity of an inhibitor of mitochondrial respiration in canine hepatocytes and adrenocortical cell cultures", TOXICOLOGY IN VITRO., vol. 10, no. 1, 1 February 1996 (1996-02-01), GB, pages 51 - 57, XP055307228, ISSN: 0887-2333, DOI: 10.1016/0887-2333(95)00102-6
XAVIER BERTAGNA ET AL: "LCI699, a Potent 11[beta]-hydroxylase Inhibitor, Normalizes Urinary Cortisol in Patients With Cushing's Disease: Results From a Multicenter, Proof-of-Concept Study", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 99, no. 4, 1 April 2014 (2014-04-01), US, pages 1375 - 1383, XP055307207, ISSN: 0021-972X, DOI: 10.1210/jc.2013-2117
COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS: "Public summary of opinion on orphan designation Osilodrostat for the treatment of Cushing's syndrome", 10 November 2014 (2014-11-10), pages 1 - 4, XP055307204, Retrieved from the Internet
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; BAILIE, MARC B. (CORRESPONDENCE) ET AL: "ATR - 101 , a selective ACAT1 inhibitor in development for adrenocortical carcinoma, disrupts steroidogenesis and causes apoptosis in normal canine adrenals.", XP002762495, retrieved from STN Database accession no. 0052299841
L.A. VERNETTI ET AL: "Differential toxicity of an inhibitor of mitochondrial respiration in canine hepatocytes and adrenocortical cell cultures", TOXICOLOGY IN VITRO., vol. 10, no. 1, 1 February 1996 (1996-02-01), GB, pages 51 - 57, XP055307228, ISSN: 0887-2333, DOI: 10.1016/0887-2333(95)00102-6
Attorney, Agent or Firm:
SUN, Eileen, S. et al. (Suite 5400701 Fifth Avenu, Seattle Washington, US)
Download PDF: